GlassScriptPhysician profile
Diane M Dingman
NPI 1922032887
$5,945.46
in general payments reported to CMS, 2019-2025
24 companies · $1,426 in 2025
The $1,426 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $630 · 2020: $452 · 2021: $855 · 2022: $871 · 2023: $937 · 2024: $775 · 2025: $1,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,137.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,211.46 | 2019-2025 | Precision 1, Rocklatan, Precision7 |
| Bausch & Lomb Americas INC. | $577.71 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Oyster Point Pharma, INC. | $513.92 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $440.21 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $375.69 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $352.01 | 2019-2021 | |
| Sight Sciences, INC. | $348.03 | 2020-2021 | |
| Kala Pharmaceuticals, INC. | $327.94 | 2021-2022 | |
| Abbvie INC. | $292.37 | 2022-2025 | Vuity, Alphagan P, Lumigan |
| Dompe US, INC. | $187.89 | 2022-2025 | Oxervate |
| Allergan, INC. | $178.13 | 2019-2022 | |
| Astellas Pharma US INC | $153.41 | 2023-2024 | Izervay |
| Horizon Therapeutics Plc | $153.07 | 2022-2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $143.08 | 2024-2025 | Xdemvy |
| Optos, INC. | $142.43 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $123.65 | 2024-2025 | Tepezza |
| Johnson & Johnson Vision Care, INC. | $119.43 | 2019-2023 | |
| Thea Pharma INC. | $101.67 | 2023-2025 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $68.59 | 2020-2021 | |
| Biotissue Holdings INC. | $39.81 | 2023 | |
| Apellis Pharmaceuticals, INC. | $38.37 | 2025 | Syfovre |
| Coopervision INC. | $23.63 | 2020 | |
| Harrow Eye, LLC | $18.92 | 2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $14.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Dingman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.